Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Core Scientific, Inc. (NASDAQ: CORZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Core Scientific operates in data processing, hosting and related services, with business segments that include digital asset self-mining, digital asset hosted mining and high-density colocation. Its SEC filings offer detailed insight into how these activities are structured, the associated risks and the company’s capital markets activity.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for narrative and quantitative information about Core Scientific’s digital infrastructure, revenue mix among self-mining, hosted mining and high-density colocation, and its stated transition toward artificial intelligence-related workloads. These reports also describe facility locations across several U.S. states and discuss operational dependencies such as access to significant electric power resources.
Current reports on Form 8-K are particularly important for tracking material events. In 2025, Core Scientific filed multiple 8-Ks regarding an Agreement and Plan of Merger with CoreWeave, Inc., the scheduling of a special meeting of stockholders, supplemental proxy disclosures, and the final voting results. A Form 8-K dated October 30, 2025 reports that stockholders did not approve the merger proposal and that the Merger Agreement was terminated, while a Form 8-K dated October 31, 2025 provides detailed vote counts.
These filings also contain extensive risk factor discussions, including the company’s ability to earn digital assets profitably, attract high-density colocation customers, secure power resources, and navigate regulatory developments affecting digital assets and high-density computing. Stock Titan enhances this information with AI-powered summaries that explain the key points of lengthy filings, highlight notable changes across reporting periods and surface items such as insider-related disclosures reported on Form 4 when available. Real-time updates from EDGAR help users monitor new CORZ filings, while AI-generated overviews make complex documents more accessible to a broad range of investors.
Core Scientific, Inc. received a Schedule 13G showing that four affiliated Susquehanna entities together report beneficial ownership of 17,376,097 shares of common stock, or 5.6% of the company, as of the event date 12/31/2025.
The percentage is based on 310,061,300 shares outstanding as of October 20, 2025, as disclosed in the company’s Form 10-Q. Holdings include common stock, options and warrants across G1 Execution Services, SIG Brokerage, Susquehanna Investment Group and Susquehanna Securities.
Each firm has sole voting and dispositive power over its own positions and shared power over all reported shares. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Barclays PLC has disclosed a small ownership stake in Core Scientific Inc. The filing reports that Barclays beneficially owns 1,302,387 shares of Core Scientific common stock, representing 0.42% of the outstanding class.
Barclays reports 1,298,420 shares with sole voting and dispositive power and 3,967 shares with shared voting and dispositive power. The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Core Scientific, Inc. received an amended Schedule 13G showing that funds managed by Valiant Capital Management report beneficial ownership of 13,120,302 shares of Common Stock, equal to 4.2% of the class. This percentage is based on 310,061,300 shares outstanding as of October 20, 2025.
The shares are held by private investment funds for the benefit of their investors, with voting and investment power shared among Valiant Capital Management, L.P., Valiant Capital Management, LLC, and Christopher R. Hansen, each reporting shared voting and dispositive power over the same 13,120,302 shares and no sole power.
The filers state that the securities were acquired and are held in the ordinary course of business, and not for the purpose, or with the effect, of changing or influencing control of Core Scientific, other than activities solely in connection with a nomination under Rule 14a-11.
Core Scientific director Jeffrey David Booth received 18,575 restricted stock units of common stock on February 4, 2026, as reported in a Form 4 filing. The grant was priced at $0 per share and will vest in full on February 3, 2027, if he continues serving as a non-employee director through that date. Following this award, Booth beneficially owns 214,262 shares of Core Scientific common stock directly.
Core Scientific, Inc. director Jordan Levy reported receiving an award of 18,575 shares of common stock on February 4, 2026 at a price of $0, reflecting a restricted stock unit grant. Following this grant, he beneficially owns 325,462 shares directly.
The restricted stock units will vest in full on February 3, 2027, provided Levy continues to serve as a non-employee director through that date.
Core Scientific, Inc. director Elizabeth Crain received a grant of 18,575 shares of common stock as restricted stock units. The award was reported as acquired at a price of $0 per share on February 4, 2026, increasing her directly held beneficial ownership to 65,348 shares.
The RSUs will vest in full on February 3, 2027, if she continues to serve as a non-employee director through that date. Until vesting, the units represent a right to receive shares rather than currently transferable stock.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.
The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific CEO Adam Taylor reported a tax-related share withholding. On 01/23/2026, 274,404 shares of Core Scientific common stock were withheld at a price of $18.79 per share to cover withholding tax obligations tied to the vesting of restricted stock units.
After this automatic withholding, Taylor directly beneficially owned 4,131,300 shares. The transaction is coded "F," indicating it was associated with equity award vesting rather than an open-market sale.
FAQ
What is the current stock price of Core Scientific (CORZ)?
What is the market cap of Core Scientific (CORZ)?
